Enhabit, Inc.

Overview

• IndustryServices-Home Health Care Services¹
• HeadquartersDallas, Texas¹
• Incorporated inDE²
• Business address6688 N. Central Expressway, Suite 1300, Dallas, Tx 75206²
• Filer categoryAccelerated filer²

See how the biggest companies compare on our leaderboards

We are a leading provider of home health and hospice services in the United States. We strive to provide our patients with superior clinical care, where our patients prefer it: in their homes. For over 25 years, we have provided care in the low-cost home setting while achieving high-quality clinical outcomes and demonstrating a consistent ability to innovate during varying economic and regulatory climates. As of December 31, 2025, we operated 249 home health and 117 hospice locations across 34 states.⁴ From its latest annual report

Corporate structure

Enhabit, Inc. sits at the top of its group. 118 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Enhabit, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

We maintain our principal executive office at 6688 N. Central Expressway, Ste. 1300, Dallas, Texas 75206, the lease for which was renewed in March 2023 for an 11 year term. See Note 6, Leases, to the accompanying consolidated financial statements for additional information about the renewal of the lease.

In addition to our principal executive office, as of December 31, 2025, we leased through various consolidated entities 280 locations. Our home health and hospice locations are in the localities served by that business and are subject to relatively small space leases, primarily of 5,000 square feet or less. Those space leases are typically five years or less in term. Our principal executive office and other properties are suitable for their respective uses and are, in all material respects, adequate for our present needs.

Item 2 of the 10-K filed Mar 5, 2026.⁴

Leadership

Who has led Enhabit, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBarbara Ann Jacobsmeyer Jun 17, 2022 to now¹²
• PresidentBarbara Ann Jacobsmeyer Jun 17, 2022 to now¹²
• Chief financial officerRyan Solomon Dec 13, 2024 to now¹³
• Chief financial officerCrissy Buchanan Carlisle Jun 17, 2022 to Jul 3, 2024¹⁴

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• A&B Home Health Solutions, LLC Delaware³
• AHM Action Home Health, LP Texas³
• AHM Texas GP, LLC Delaware³
• AHM Texas Holdings, Inc. Delaware³
• AHM Texas LP, Inc. Delaware³
• Abba Home Health, L.P. Texas³
• Advanced Homecare Home Office, LLC Delaware³
• Advanced Homecare Management, LLC Delaware³
• Apex Hospice LLC Texas³
• Best Home Care LP Texas³
• CS Health & Wellness, LLC Georgia³
• Camellia Home Health of Alabama, LLC Alabama³
• Camellia Home Health of East Tennessee, LLC Delaware³
• Camellia Home Health of the Gulf Coast, LLC Mississippi³
• Camellia Hospice of Central Mississippi, LLC Mississippi³
• Camellia Hospice of East Louisiana, LLC Delaware³
• Camellia Hospice of Louisiana, LLC Delaware³
• Camellia Hospice of North Mississippi, LLC Mississippi³
• Camellia Hospice of Northeast Alabama LLC Alabama³
• Camellia Hospice of Northeast Mississippi, LLC Mississippi³
• Camellia Hospice of South Alabama, LLC Mississippi³
• Camellia Hospice of Southwest Mississippi, LLC Mississippi³
• Camellia Hospice of the Gulf Coast, LLC Mississippi³
• Camellia Medical Systems, Inc. Mississippi³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• Encompass Health Home Health Holdings, Inc.May 12, 2020 to Oct 1, 2020²

Timeline

1. May 15, 20268-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer³⁶
2. May 12, 20268-K Shareholder vote; Other events³⁷
3. May 5, 20268-K Other events³⁸
4. Apr 16, 20268-K Other events³⁹
5. Mar 5, 20268-K Results of operations; Regulation FD disclosure⁴⁰
6. Mar 4, 20268-K Entered a material agreement; New debt or obligation⁴¹
7. Feb 27, 20268-K Executive or director change⁴²
8. Feb 23, 20268-K Entered a material agreement; Regulation FD disclosure⁴³
9. Feb 12, 20268-K Regulation FD disclosure⁴⁴
10. Dec 9, 20258-K Regulation FD disclosure⁴⁵
11. Nov 5, 20258-K Results of operations; Regulation FD disclosure⁴⁶
12. Sep 29, 20258-K Regulation FD disclosure⁴⁷
13. Jun 17, 2022New chief executive Barbara Ann Jacobsmeyer becomes CEO¹²

Calendar

When it reported results

1. Mar 5, 2026Reported quarterly or annual results⁴⁰
2. Nov 5, 2025Reported quarterly or annual results⁴⁶
3. Aug 6, 2025Reported quarterly or annual results⁴⁸
4. May 7, 2025Reported quarterly or annual results⁴⁹
5. Mar 5, 2025Reported quarterly or annual results⁵⁰
6. Nov 6, 2024Reported quarterly or annual results⁵¹
7. Aug 6, 2024Reported quarterly or annual results⁵²
8. Jul 15, 2024Reported quarterly or annual results⁵³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

420 filings to the SEC since October 2021: 8 annual reports, 12 quarterly reports, 50 major events, 255 insider forms, 22 large holders, 73 other. The latest 20:

1. Aug 13, 2026SCHEDULE 13G/A EDGAR
2. May 26, 202615-12G EDGAR
3. May 15, 20264 EDGAR
4. May 15, 20264 EDGAR
5. May 15, 20264 EDGAR
6. May 15, 20264 EDGAR
7. May 15, 20264 EDGAR
8. May 15, 20264 EDGAR
9. May 15, 20264 EDGAR
10. May 15, 20264 EDGAR
11. May 15, 2026S-8 POS EDGAR
12. May 15, 2026S-8 POS EDGAR
13. May 15, 20264 EDGAR
14. May 15, 20264 EDGAR
15. May 15, 20264 EDGAR
16. May 15, 20264 EDGAR
17. May 15, 20264 EDGAR
18. May 15, 20264 EDGAR
19. May 15, 20268-K EDGAR
20. May 15, 2026SCHEDULE 13G/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 35 buys and 5 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• James E. FlynnSCHEDULE 13G/A, 4 filings Oct 14, 2022 to Aug 13, 2026⁵⁴
• BALYASNY ASSET MANAGEMENT L.P.SCHEDULE 13G/A, 1 filing May 15, 2026⁵⁵
• 8 KNOTS MANAGEMENT, LLCSCHEDULE 13G/A, 6 filings Nov 14, 2024 to Apr 10, 2026⁵⁶
• VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Aug 10, 2022 to Mar 26, 2026⁵⁷
• BlackRockSC 13G/A, 6 filings Aug 9, 2022 to Oct 7, 2024⁵⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Enhabit, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAREnhabit, Inc.¹
• CIK0001803737
• Employer ID (EIN)47-2409192⁴
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)8082 Services-Home Health Care Services¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address6688 N. Central Expressway, Suite 1300, Dallas, TX 75206¹
• Phone4696216419¹
• Shares outstanding51,225,606 as of May 4, 2026¹¹
• Public float$480.1M as of Jun 30, 2025⁴
• AuditorPricewaterhouseCoopers LLP, Dallas, Texas PCAOB ID 238; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceMay 12, 2020¹
• Filings427 in all: 4 (218), 8-K (48), 3 (25), DEFA14A (24), 10-Q (12), 4/A (12), DFAN14A (10), SC 13G/A (10)¹
  All 40 form types

  SCHEDULE 13G/A (7), UPLOAD (6), 10-K (4), 10-K/A (4), 424B5 (4), CORRESP (4), SC 13G (4), ARS (3), 10-12B/A (2), 144 (2), 8-K/A (2), DEF 14A (2), DEFC14A (2), PREC14A (2), S-8 (2), S-8 POS (2), 10-12B (1), 15-12G (1), 25-NSE (1), CERT (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-K (1), POSASR (1), PRE 14A (1), PREM14A (1), PRRN14A (1), S-3ASR (1), SCHEDULE 13G (1), SEC STAFF ACTION (1)

• Latest filingsAnnual report (10-K) Mar 5, 2026
  Quarterly report (10-Q) May 7, 2026
  Proxy statement (DEF 14A) May 16, 2025
  Latest 8-K (8-K) May 15, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Enhabit, Inc. names in Item 1A of its 10-K filed Mar 5, 2026: 33 risks under these headings, as written.⁴

• Risks Related to the Proposed Merger with Kinderhook
• The proposed Merger is subject to the satisfaction of certain closing conditions, including government consents and approvals, some or all of which may not be satisfied or completed within the expected timeframe, if at all.
• We may not complete the proposed Merger within the time frame we anticipate or at all, which could have an adverse effect on our business, financial position, results of operations, and cash flows.
• We will be subject to various uncertainties while the Merger is pending that may cause disruption and may make it more difficult to maintain relationships with employees, patients, providers, and payers.
• We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger.
• Litigation challenging the Merger Agreement may prevent the Merger from being consummated within the expected timeframe or at all.
• Risks Related to Our Business
• Reimbursement Risks
• Reductions or changes in reimbursement rates from government programs, or new government regulations, could adversely affect our Net service revenue and other operating results.
• An increase in Medicare Advantage patients and resulting change in our payer mix could adversely affect our Net service revenue or our profitability.
• Efforts to reduce payments to healthcare providers undertaken by third-party payers, conveners, and referral sources could adversely affect our revenues and profitability.
• We face periodic and routine reviews, audits, and investigations under our contracts with federal and state government agencies and private payers, and these audits could have adverse findings that may negatively impact our business.

Legal proceedings

We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. Some of these matters have been material to us in the past, and others in the future may, either individually or in the aggregate, be

material and adverse to our business, financial position, results of operations, and liquidity. We do not believe any of our pending legal proceedings are material to us, but there can be no assurance our assessment will not change based on future developments.

Additionally, the FCA allows relators to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as “qui tam” actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys’ fees, and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. For additional discussion regarding the FCA, see Item 1A, “Risk Factors—Risks Relating to Our Business—Other Regulatory Risks.”

The opening of Item 3, Legal Proceedings.⁴